| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Aptevo Therapeutics Inc.$3.94
-0.19 (-4.82%)
D 26Pipeline Score Overvalued Biotech · Clinical
Market Cap
6.28 M
EPS
-203.74
P/E Ratio
-0.02 $
Value Trade
639.40 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
3.92 M
Operating CF
-7.96 M
Total Assets
19.90 M
Total Liabilities
8.29 M
Equity
11.61 M
D/E Ratio
12,345
6 %
Week
-7.2 %
1 Month
-28.26 %
3 Month
-75 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
14.53 M
Monthly Burn
2.65 M
Runway
3.8 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
45.27 K
52 Week Range
3.80 - 235.98
% held by Insiders
7.97 %
% held by Institutions
6.05 %
Enterprise Value
-3.82 M
Total Shares
1.18 M
Short %
6.73 %
Float Shares
1.18 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aptevo Therapeutics Inc.
433Total events
3Upcoming
96Tier-1 (high impact)
2016 – 2026Coverage
Upcoming catalysts 3
Event history 430
May 27, 2026
▲Partnership / LicenseCorporate
50/50 strategic collaboration with Niowave to develop up to three radiopharmaceutical programs
oncologysource ↗
May 27, 2026
▼Equity OfferingCorporate
Niowave makes at-the-market equity investment in Aptevo at closing, initial ownership 7.9%
May 27, 2026
▲Trial InitiationTrial
First stage of collaboration designed and ready to initiate, targeting Nectin-4 with Actinium-225
solid tumors (Nectin-4 expressing)source ↗
May 13, 2026
▲Topline ReadoutmipletamigClinical Data
Mipletamig data update in frontline AML: 87% clinical benefit rate, 81% CR/CRi, no CRS
frontline acute myeloid leukemiasource ↗
May 6, 2026
▲Topline ReadoutmipletamigClinical Data
Reported 87% clinical benefit and 81% remission in 31 evaluable frontline AML patients through Cohort 5
acute myeloid leukemia (AML)source ↗
May 6, 2026
●Enrollment UpdatemipletamigTrial
Enrollment in Cohort 6 nearing completion
acute myeloid leukemia (AML)source ↗
Apr 1, 2026
◆Management ChangeCorporate
Marvin White to retire as CEO and become Executive Chair; Jeff Lamothe to become President and CEO
Mar 31, 2026
Mar 26, 2026
▲Topline ReadoutmipletamigClinical Data
Updated interim results from 28 evaluable frontline AML patients: 86% clinical benefit rate, 79% CR/CRi, 61% CR, no CRS
frontline acute myeloid leukemiasource ↗
Mar 26, 2026
●Management ChangeCorporate
Marvin White transitions to Executive Chair; Jeff Lamothe becomes President and CEO
Drug Pipeline Intelligence
D26
Pipeline Score $1M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.2x
rNPV / MCap Top 27%
Micro Cap (rank 666 of 911)
Percentile RankAptevo Therapeutics Inc. faces pipeline headwinds (26/100), with $462M risk-adjusted pipeline value, led by ES414 in Prostate Cancer (Phase 1), across $50B in total addressable markets, but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ES414 Monoclonal antibody | Prostate Cancer | Phase 1 | NCT02262910 | 9% | $355M | COMPLETED | 35 | - | - | Feb 18, 2019 | - | Aug 28, 2019 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
mipletamig | acute myeloid leukemia | — | 2026-05-13 | clinical benefit rate: 87%; remission rate: 81%; complete remission rate: 65%; blast reduction: 52% Read More | Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection Read More | |
mipletamig | acute myeloid leukemia | — | 2026-05-13 | clinical benefit rate: 87%; remission rate: 81%; complete remission rate: 65%; blast reduction: 52% Read More | Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection Read More | |
mipletamig | acute myeloid leukemia | — | 2026-05-13 | clinical benefit rate: 87%; remission rate: 81%; complete remission rate: 65%; blast reduction: 52% Read More | Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in APVO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
APVO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
APVOAptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing 50/50 strategic collaboration will develop up to three radioph
Aptevo Therapeutics and Niowave have announced a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs. This partnership, which includes an equity investment from Niowave, aims to leverage Aptevo's multispecific immuno-oncology capabilities alongside Niowave's expertise in radioisotope production. The collaboration focuses on utilizing a clinically validated cancer target, Nectin-4, for novel treatment options aimed at addressing difficult-to-treat cancers. This marks a significant expansion for Aptevo into the growing field of radiopharmaceutical development.
Read more →APVOAptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Aptevo Therapeutics provided a business update highlighting the promising performance of mipletamig in frontline acute myeloid leukemia (AML), achieving an 87% clinical benefit rate. The company completed its leadership transition, appointing Jeff Lamothe as CEO. Additionally, Aptevo secured a $60 million equity line to enhance financial flexibility as it advances its clinical programs.
Read more →APVO▼ -7.7%on this news
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection Progra
Aptevo Therapeutics has reported promising results from its RAINIER trial, demonstrating an impressive 87% clinical benefit rate and an 81% remission rate among 31 evaluable frontline acute myeloid leukemia (AML) patients. The study, which combines the drug mipletamig with venetoclax and azacitidine, is now in its final stage of dose optimization, with results indicating a strong and consistent profile of clinical activity. The company is on track to complete the trial and select the recommended Phase 2 dose within the year, positioning itself for further advancements in AML treatment. Notably, the absence of cytokine release syndrome highlights the safety profile of mipletamig.
Read more →APVOAptevo Provides State of the Business Report and 2025 Financial Results Latest mipletamig data delivers 86% clinical benefit rate with no cytokine release syndrome in 28 frontline AML patients, supporting its potential t
Aptevo Therapeutics Inc. reported significant progress regarding its mipletamig therapy, achieving an 86% clinical benefit rate in frontline AML patients without any cytokine release syndrome. The company has expanded its CD3 therapy pipeline and introduced its first trispecific drug candidates. Financially, Aptevo strengthened its capital base with a new $60 million equity line, which is expected to support its operations through 2029. The company is optimistic about the potential of mipletamig to enhance existing AML treatments.
Read more →APVO▼ -22.8%on this news· ran to -34% by day 1
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy
Aptevo Therapeutics has announced new interim data for its drug mipletamig, which shows an 86% clinical benefit rate in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia (AML) patients. Notably, no cases of cytokine release syndrome (CRS) were reported among participants. The results particularly highlight the safety and tolerability of mipletamig, making it a promising candidate to enhance current AML treatments for elderly or unfit patients. The data supports the potential of mipletamig to improve outcomes for those facing poor prognoses in this patient group.
Read more →APVO▼ -10.3%on this news
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into 2026 and beyon
Aptevo Therapeutics has announced upcoming executive leadership transitions as part of its strategy to support growth and execute long-term objectives. Marvin White will transition from CEO to Executive Chair, while Jeff Lamothe will take over as the new CEO. The leadership change reflects continuity, with all leaders having been part of Aptevo since its inception in 2016. The company aims to leverage its validated technology and expanded pipeline to further patient impact in the oncology space while ensuring strong operational execution.
Read more →APVO▲ +5%on this news
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Aptevo Therapeutics has secured a $60 million equity line of credit to enhance its financial flexibility and support its clinical and preclinical pipeline. This funding will allow the company to access capital incrementally and is expected to extend its financial runway into 2029. The company plans to use these funds to advance its multispecific anti-cancer agents, including mipletamig, which has shown promising clinical results.
Read more →APVO▼ -9.4%on this news
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
Aptevo Therapeutics has announced a 1-for-18 reverse stock split, effective December 29, 2025. This decision was approved by stockholders and aims to reduce the number of outstanding shares from approximately 18 million to about 1 million. The split is intended to enhance the stock's marketability while maintaining the par value of the shares.
Read more →APVOxfeff; Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update 89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trials Introduces first
Aptevo Therapeutics reported its financial results for Q3 2025, highlighting a substantial 89% remission rate in evaluable patients treated with mipletamig for frontline AML. The company introduced two new trispecific T-cell engagers, APVO451 and APVO452, aimed at overcoming immune suppression in solid tumors. Despite a significant rise in cash reserves, the company experienced a net loss of $7.5 million, reflecting increased research and development costs.
Read more →APVOMipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable safety and tolera
Aptevo Therapeutics announced a 100% remission rate in Cohort 3 of its RAINIER trial evaluating mipletamig for newly diagnosed AML patients unfit for intensive chemotherapy. This first-in-class bispecific antibody displayed a clean safety profile, with no dose-limiting toxicities or cytokine release syndrome observed to date. Additionally, the trial demonstrated that 40% of patients achieved minimal residual disease negative status, indicating a promising pathway for treatment. Cohort 4 is now open for enrollment, potentially expanding mipletamig's clinical impact further.
Read more →APVOAptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEX  design to target prostat
Aptevo Therapeutics has announced the expansion of its oncology pipeline with two new trispecific candidates, APVO452 and APVO451, designed to target prostate and multiple solid tumor cancers. These new molecules leverage the proprietary ADAPTIR-FLEX platform and build on clinical validation from mipletamig. With the addition of these candidates, Aptevo now offers eight bispecific and trispecific therapeutic candidates, demonstrating its focus on innovation in cancer treatment. The trispecific approach aims to enhance anti-tumor responses while minimizing systemic toxicity.
Read more →APVOAptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO45
Aptevo Therapeutics has reported its financial results for the second quarter of 2025, showcasing significant advancements in its clinical pipeline. The firm’s lead candidate, mipletamig, has demonstrated an impressive 85% remission rate in frontline acute myeloid leukemia (AML) patients. Additionally, Aptevo has expanded its CD3 bispecific portfolio with the introduction of APVO455, targeting multiple solid tumors. Financially, the company secured $15.9 million in funding, extending its cash runway to late 2025, despite reporting a net loss for the quarter.
Read more →APVO▲ +81.9%on this news
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules SEATTLE, WA –
Aptevo Therapeutics Inc. has announced an $8 million offering priced at-the-market under Nasdaq rules. The offering includes 2,465,000 shares of common stock and warrants for an aggregate of 12,325,000 shares. The funds will be used for clinical development and general corporate purposes, with the offering expected to close around June 20, 2025. The success of this offering depends on stockholder approval and market conditions.
Read more →APVO▼ -21.1%on this news· ran to -39% by day 3
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan SEATTLE, WA / ACCESSWIRE /
Aptevo Therapeutics Inc. has announced a 1-for-20 reverse stock split to ensure compliance with Nasdaq's continued listing standards, set to take effect on May 23, 2025. This consolidation will reduce the number of outstanding shares significantly and is aimed at enhancing market perception. Approved by stockholders on May 14, the decision was finalized by the board on May 21. Despite the intended benefits, such actions can often raise concerns among investors regarding the company's financial health.
Read more →APVOAPTEVO THERAPEUTICS REPORTS 1Q25 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON MIPLETAMIG 9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trials Mipletamig triplet combination
Aptevo Therapeutics (APVO) reported strong clinical trial results for mipletamig, showing that 90% of frontline AML patients achieved remission. The ongoing RAINIER trial continues to demonstrate a favorable safety profile, with no cytokine release syndrome reported. The company disclosed a net loss of $6.3 million for Q1 2025, although this marked an improvement compared to the same period last year. Aptevo is focusing on advancing its clinical trials and plans to share multiple data readouts throughout 2025.
Read more →APVOAptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SEATTLE, WA –
Aptevo Therapeutics has entered into definitive agreements for a registered direct offering of 2,324,000 shares at a price of $0.862 per share, expected to close shortly. The offering aims to generate approximately $2.0 million for continued clinical development and working capital. Roth Capital Partners is the exclusive placement agent for the offering, which aligns with Aptevo's focus on innovative cancer therapies using their proprietary platform technologies. However, the low offering price could raise questions about market perception.
Read more →APVOAptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules SEATTLE, WA –
Aptevo Therapeutics has announced a $2.1 million registered direct offering and concurrent private placement under Nasdaq rules. This offering, which includes the sale of shares and warrants, is expected to close on April 4, 2025, pending customary conditions. Proceeds from this financing will be directed towards the continued development of their clinical candidates and other corporate purposes. Roth Capital Partners serves as the exclusive placement agent for this offering.
Read more →APVOMarch 2025 | Nasdaq: APVO Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements
Aptevo Therapeutics has presented forward-looking statements detailing its expectations for clinical programs focused on bispecific therapeutics, including mipletamig for acute myeloid leukemia (AML). The company outlines the potential for strong efficacy and safety in its candidates, alongside the possibility for multiple indications across various oncology sectors. While the therapeutic pipeline shows promise with possible near-term catalysts, Aptevo also cautions investors about the inherent risks and uncertainties tied to clinical trial outcomes and regulatory approvals.
Read more →APVOAPTEVO THERAPEUTICS REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE 100% of Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patient
Aptevo Therapeutics has reported promising results for its oncology pipeline, notably that 100% of patients in Cohort 1 of the mipletamig RAINIER trial for frontline acute myeloid leukemia (AML) achieved remission within 30 days. Additionally, the company highlighted a 59% stable disease rate from Phase 1 trials of ALG.APV-527 targeting multiple solid tumors. Financially, Aptevo closed 2024 with $8.7 million in cash and a decrease in research expenses, implying strategic shifts in their clinical focus as they prepare for multiple upcoming data readouts in 2025.
Read more →APVOCONFIDENTIAL 11, February 2025 | Nasdaq: APVO Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, o
Aptevo Therapeutics recently presented forward-looking statements regarding its therapeutic candidates, particularly mipletamig, designed for acute myeloid leukemia (AML). The company highlighted the promising results from its Phase 1b/2 trials, which exhibit both safety and efficacy in combination with standard treatments. Aptevo also emphasized the potential for its diversified pipeline to target various solid tumors. They cautioned stakeholders about the inherent uncertainties and variability in clinical trial outcomes, emphasizing the need for cautious investment.
Read more →APVOof Patients Achieve Remission within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial Two of three patients achieved both complete remission and MRD-negative status High response rates observed in earlier
Aptevo Therapeutics announced that all patients in Cohort 1 of the RAINIER frontline AML Phase 1b trial achieved remission within 30 days. Notably, two of three patients reached MRD-negative status, indicating complete elimination of cancer cells. These results build on previous successes in prior trials, reinforcing mipletamig's potential to transform AML treatment methods. The favorable safety profile of mipletamig continues to be a key aspect as the company prepares for enrollment of Cohort 2 in the study.
Read more →APVOBispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects Powered by Aptevo's proprietary ADAPTIR-FLEX  platform, antibody innovation ta
Aptevo Therapeutics has announced advancements in its bispecific antibody APVO442, designed to target prostate cancer with enhanced precision and reduced side effects. Utilizing the proprietary ADAPTIR-FLEX platform, APVO442 aims to activate T cells against tumor cells while sparing healthy cells. Given the growing prostate cancer treatment market, which is projected to reach over $24 billion in the next decade, APVO442 could play a significant role in this evolving landscape. However, its clinical efficacy remains to be validated in upcoming trials.
Read more →APVOProving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation Aptevo's Peter Pavlik, PhD, to chair a session on “Bi and Multispecific Biologicsȁ
Aptevo Therapeutics is set to highlight its ADAPTIR technology at the Cambridge Healthcare Institute's Pep Talk conference in January 2025. Peter Pavlik, PhD, will chair a session focused on bi and multispecific biologics, showcasing how Aptevo's platforms enable rapid therapeutic design. The presentation will also cover clinical candidates Mipletamig and ALG.APV-527, which exemplify the potential of modular biotherapeutics. Despite the optimism surrounding Aptevo's developments, the company acknowledges inherent risks associated with forward-looking predictions.
Read more →APVOAptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm Developing innovative b
Aptevo Therapeutics is emphasizing the potential of its robust oncology pipeline featuring bispecific antibodies aimed at treating challenging cancers. The lead candidate, mipletamig, is currently undergoing a Phase 1b/2 trial with promising results showing a 90% reduction in leukemic blasts in a patient with acute myeloid leukemia. Additionally, the clinical candidate ALG.APV-527 has demonstrated positive early safety and efficacy results for solid tumors. With the bispecific antibody market expanding, Aptevo's innovative approach to cancer treatment positions it favorably in the industry.
Read more →APVOFirst Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies Potential to re
Aptevo Therapeutics announced that the first patient dosed in the ongoing RAINIER trial achieved a remarkable 90% reduction in leukemic blasts within 30 days of treatment. The trial is evaluating mipletamig, a CD3 x CD123 bispecific antibody, in combination with standard therapies for frontline treatment of Acute Myeloid Leukemia (AML). Initial data from earlier trials have indicated strong safety and efficacy profiles, bolstering interest among the cancer treatment community. The FDA has approved the RAINIER trial to proceed, allowing an exploration of mipletamig's potential benefits in newly diagnosed patients.
Read more →APVOAPTEVO THERAPEUTICS REPORTS 3Q 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Company Achieves Milestones in Both Clinical Programs Initiates Mipletamig Phase 1b/2 Clinical Trial, “RAINIER,” in Front
Aptevo Therapeutics Inc. reported its financial results for Q3 2024, highlighting significant milestones in its clinical programs. The company has initiated the Phase 1b/2 trial of mipletamig for AML patients and presented positive interim data for ALG.APV-527 at the ESMO Congress. Financially, Aptevo raised $5.75 million during the quarter, though it still recorded a net loss of $5.1 million, a reduction from the previous year's loss. The company aims to leverage these developments for growth and success in 2025.
Read more →APVOAptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules SEATTLE, WA –
Aptevo Therapeutics has announced a $3.0 million offering through a registered direct offering under Nasdaq rules, allowing for the purchase of common stock and warrants. The proceeds are intended for the continued clinical development of its immuno-oncology therapies. The expected close date for the offering is September 18, 2024, pending customary conditions. However, the exercise of warrants is contingent upon stockholder approval, and market conditions introduce inherent risks to this financial move.
Read more →APVOAptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study Early Data Indicate Clinical Activity i
Aptevo Therapeutics and Alligator Bioscience announced encouraging interim results from their Phase 1 trial of ALG.APV-527, a bispecific antibody for solid tumors. 60% of evaluable patients achieved stable disease, with the longest duration noted in a breast cancer patient at over 11 months. The trial demonstrated a positive safety and tolerability profile, with favorable pharmacokinetics evident in all patients. These findings were presented at the European Society for Medical Oncology Congress, highlighting the potential clinical benefits of ALG.APV-527 for patients with solid tumors.
Read more →APVOAPTEVO THERAPEUTICS REPORTS 2Q 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE SEATTLE, WA –
Aptevo Therapeutics Inc. reported its financial results for Q2 2024, showcasing significant progress in its clinical programs. The company is preparing to launch its Phase 1b/2 trial for APVO436, which demonstrated a 91% clinical benefit rate in previous trials for Acute Myeloid Leukemia. Furthermore, Aptevo has secured $2.75 million in funding, extending its cash runway through 2025. Despite a net loss of $5.9 million in the quarter, the ongoing clinical trials indicate positive outcomes and patient tolerability.
Read more →APVOAptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules SEATTLE, WA / ACCESSWIRE /
Aptevo Therapeutics has announced a $2.75 million offering of common stock and warrants to healthcare-focused institutional investors. The registered direct offering is priced at $0.515 per share and is expected to close on July 1, 2024. The company intends to use the proceeds for clinical development, working capital, and general corporate purposes. The offering also includes an amendment to existing warrants, reducing their exercise price to the same $0.515 per share, pending stockholder approval. Aptevo warns investors of potential market and regulatory risks affecting its future performance.
Read more →APVOAPTEVO THERAPEUTICS REPORTS 1Q 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after
Aptevo Therapeutics reported its Q1 2024 financial results, highlighting the success of a heavily pre-treated breast cancer patient who achieved stable disease while participating in the ALG.APV-527 trial. The company is on track to begin a Phase 1b/2 trial evaluating APVO436 in combination with venetoclax and azacitidine for treating frontline acute myeloid leukemia. Despite progress in clinical programs, Aptevo reported a net loss of $6.8 million, reflecting challenges in financial performance during this period.
Read more →APVOAptevo Therapeutics Announces Pricing of $4.6 Million Public Offering SEATTLE, WA –
Aptevo Therapeutics has announced the pricing of a public offering amounting to $4.6 million, involving the issuance of 3.4 million shares of common stock along with warrants for additional shares. The proceeds are intended for the clinical development of their products and related corporate activities. The offering is set to close around April 15, 2024, contingent on customary conditions. The announcement comes with an acknowledgment of potential risks and uncertainties impacting the company's future performance.
Read more →APVOAlligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4 Initial interim data show favorable dr
Alligator Bioscience and Aptevo Therapeutics have announced positive interim data from the Phase 1 trial of ALG.APV-527, designed for solid tumors expressing the tumor antigen 5T4. The trial, which is currently more than 50% enrolled, has shown favorable drug exposure and confirmed biological activity. Preliminary results indicate promising clinical activity in heavily pretreated patients. The trial will continue to assess safety, pharmacokinetics, and potential anti-tumor activity, with results expected to be reported in the second half of 2024.
Read more →APVOAPTEVO THERAPEUTICS REPORTS 2023 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expec
Aptevo Therapeutics Inc. has released its financial results for 2023, detailing a net loss of $17.4 million and plans for ongoing research. The company aims to advance its lead candidate, APVO436, for treating frontline acute myeloid leukemia, following promising trial results indicating a 91% clinical benefit rate. In addition, Aptevo has enrolled patients in a Phase 1 trial for its candidate ALG.APV-527 and expects interim results for both candidates in the near future. Overall, despite financial losses, the company maintains a positive outlook based on recent clinical data and future development plans.
Read more →APVOAPTEVO THERAPEUTICS REPORTS 3Q23 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE The Company's ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues to Progress Planning for APVO436 Phase 2 Tria
Aptevo Therapeutics Inc. announced its third-quarter financial results and business updates, revealing ongoing progress in its ALG.APV-527 Phase 1 trial for multiple solid tumors. The company reported a net loss of $6.3 million, but this was an improvement compared to the previous year's loss. With $7 million raised in funding, Aptevo plans to advance its pipeline, including preparations for a Phase 2 trial of APVO436 in AML. The data presented indicated promising outcomes for APVO436 combined with standard chemotherapy agents.
Read more →APVOAPTEVO THERAPEUTICS REPORTS 2Q23 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Positive Duration of Remission Data Adds to Growing Body of Clinical Evidence Supporting APVO436 for the Treatment of AML APVO436 Poised f
Aptevo Therapeutics Inc. has reported its second quarter financial results and revealed positive duration of remission data for its lead candidate, APVO436, used in combination with venetoclax and azacitidine for AML treatment. The encouraging data indicates that 82% of patients responded well, with some transitioning to stem cell transplants. The company also announced a $5 million equity raise to support ongoing clinical trials, while facing a reported net loss of $7.9 million during the quarter.
Read more →APVOAptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML Phase 2 Trials in Relapsed/Refractory and Frontline Settings Planned, APVO436 to be administere
Aptevo Therapeutics Inc. announced positive results from its Phase 1b trial of the bispecific drug APVO436, which targets acute myeloid leukemia (AML). In the trial, APVO436 demonstrated a strong response rate when combined with venetoclax and azacitidine. The company plans to advance to Phase 2 trials for both relapsed/refractory and frontline patients by mid to late 2023. Overall, the trial results add to the growing clinical evidence in favor of APVO436's therapeutic potential in treating AML.
Read more →APVOAPTEVO THERAPEUTICS REPORTS 1Q23 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Company Achieves Multiple Clinical and Preclinical Milestones and Raises $9.7 Million in Non-Dilutive Funding, Elimina
Aptevo Therapeutics Inc. reported its financial results for Q1 2023, showcasing significant advancements in its clinical programs. The company raised $9.7 million in non-dilutive funding and eliminated its existing debt, suggesting strong financial health. Notable developments included the initiation of a Phase 1 trial for ALG.APV-527 and plans for a Phase 2 program for APVO436, bolstered by positive previous results. Additionally, Aptevo introduced a new compound, APVO711, aimed at enhancing cancer treatment through a dual mechanism of action.
Read more →APVOAptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding Completes Sale of IXINITY Deferred Payments and Portion of Milestones from Medexus to XOMA Corporation SEATTLE, WA –
Aptevo Therapeutics announced a raise of $9.6 million in non-dilutive funding, achieved through the sale of IXINITY deferred payments and milestones to XOMA Corporation. This funding extends their cash runway beyond 12 months and positions the company as debt-free. Aptevo retains rights to potential future milestones related to IXINITY's sales and regulatory approvals. The company aims to focus on advancing its cancer immunotherapy programs amidst ongoing market challenges.
Read more →APVOAPTEVO THERAPEUTICS REPORTS 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Company Achieves Multiple Clinical and Scientific Milestones in 2022, Poised for APVO436 Phase 2 in AML 2H23, ALG.APV-527 dosing initiated 1
Aptevo Therapeutics has reported its financial results for 2022 along with significant business updates. Key milestones include positive clinical outcomes for APVO436 in AML and the initiation of a Phase 1 trial for ALG.APV-527 targeting solid tumors. The company is poised to start a Phase 2 trial for APVO436 in the latter half of 2023, leveraging favorable safety and efficacy data. Overall, Aptevo demonstrated considerable progress in its clinical and preclinical pipeline despite market challenges.
Read more →APVOAlligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial Trial to Evaluate Safety, Tolerability and Clinical Activity in Solid Tumors Expressing 5T4 Lund, Swe
Alligator Bioscience and Aptevo Therapeutics have announced the dosing of the first patient in a Phase 1 clinical trial evaluating ALG.APV-527, a bispecific antibody targeting solid tumors expressing the 5T4 antigen. This trial aims to assess the safety, tolerability, and clinical activity of the therapeutic. The study is notably a multi-center and open-label trial set to include multiple cohorts of patients with various solid tumor types. Both companies express optimism about the potential of ALG.APV-527 to stimulate immune responses with a favorable safety profile, highlighting a significant advancement in their collaborative efforts and clinical development.
Read more →APVOAptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors New PD-L1 x CD40 Candidate Built on Proprietary ADAPTIR Platform, Enters Pre-Clinical Pipelin
Aptevo Therapeutics has filed a provisional patent for its fifth bispecific antibody, APVO711, targeting PD-L1 and CD40 to treat solid tumors. The new candidate, based on the proprietary ADAPTIR platform, aims to initiate preclinical studies this year. APVO711 is designed to synergistically activate T cells by blocking the PD-L1/PD-1 pathway and stimulating CD40 receptor activation. This development adds to Aptevo's growing portfolio of immuno-oncology therapies.
Read more →APVOClinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Na ve Patients with Acute Myeloid Leukemia (AML) Aptevo Therapeutics Plans a Pha
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Na ve Patients with Acute Myeloid Leukemia (AML) Aptevo Therapeutics Plans a Phase 2 Trial in 2H23 in Frontline and Relapsed/Refractor
Read more →APVOAptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights Company to Present New APVO436 Expansion Phase Trial Data at Upcoming American Society of Hematology Annual M
Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights Company to Present New APVO436 Expansion Phase Trial Data at Upcoming American Society of Hematology Annual Meeting and Exposition SEATTLE, WA - November 10, 2022 - Aptevo Therapeutics Inc.
Read more →APVOAlligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tu
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tumor antigens in multiple solid tumor types Lund, Sweden, a
Read more →APVOAptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights SEATTLE, WA
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights SEATTLE, WA - August 11, 2022 - Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ: APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology thera
Read more →APVOAptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia Cohort 1 Combination Therapy
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Pati
Read more →APVOAptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights SEATTLE, WA
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and SEATTLE, WA - May 12, 2022 - Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ: APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its pro
Read more →APVOAPTEVO THERAPEUTICS REPORTS 2021
APTEVO THERAPEUTICS REPORTS 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE SEATTLE, WA - March 24, 2022 - Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPT
Read more →APVOAptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE , Provides Company Update APVO436 Phase 1b Trial for Acute Myeloid Leukemia Adds New Site Complete Remission Patient to Advance to
Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE , Provides Company Update APVO436 Phase 1b Trial for Acute Myeloid Leukemia Adds New Site Complete Remission Patient to Advance to Transplant SEATTLE, WA - February 9, 2022 - Aptevo Thera
Read more →APVOAptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective
Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022 Vice Chairman, John E. Niederhuber, M.D., to Assume Chairmanship, Effective April 1, 2022 SEATTLE, WA - January 21, 2022 - Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NAS
Read more →APVOAptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia SEATTLE, WA
Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia SEATTLE, WA - November 23, 2021 - Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:
Read more →APVOThere are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration
APTEVO THERAPEUTICS REPORTS THIRD QUARTER FINANCIAL RESULTS WITH BUSINESS HIGHLIGHTS SEATTLE, WA - November 12, 2021 - Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ: APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeu
Read more →APVOAptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) o
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with
Read more →APVOof data from ongoing clinical trials, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competit
APTEVO THERAPEUTICS REPORTS SECOND QUARTER FINANCIAL RESULTS WITH BUSINESS HIGHLIGHTS SEATTLE, WA - August 12, 2021 - Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ: APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeut
Read more →APVOAPTEVO THERAPEUTICS ANNOUNCES EXPANSION PHASE OF LEAD ANTI-LEUKEMIA DRUG APVO436 IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation P
APTEVO THERAPEUTICS ANNOUNCES EXPANSION PHASE OF LEAD ANTI-LEUKEMIA DRUG APVO436 IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the Trial SEATTLE, WA /May 27, 2021 / Aptevo Thera
Read more →APVOAPTEVO THERAPEUTICS REPORTS POSITIVE PHASE 1 CLINICAL DATA FOR ITS LEAD LEUKEMIA DRUG CANDIDATE APVO436 IN ADULTS WITH RELAPSED ACUTE MYELOID LEUKEMIA Dose Escalation Study of APVO436 Shows Favorabl
APTEVO THERAPEUTICS REPORTS POSITIVE PHASE 1 CLINICAL DATA FOR ITS LEAD LEUKEMIA DRUG CANDIDATE APVO436 IN ADULTS WITH RELAPSED ACUTE MYELOID LEUKEMIA Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side E
Read more →APVOAPTEVO THERAPEUTICS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohor
APTEVO THERAPEUTICS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA - May 11, 2021 - Aptevo Therapeutics Inc. ("Aptevo" or
Read more →APVOAPTEVO THERAPEUTICS REPORTS 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome;
APTEVO THERAPEUTICS REPORTS 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Enrollment in Cohort 10 Ongoing Completes Sale of RUXIENCE Royalty Payments for
Read more →APVOThese reserves wer e based on the amounts earned or to be claimed on the related sales and were classified as reductions of accounts receivable (if the amount wa s payable to the customer) or a current liability (if the
Aptevo Therapeutics, Inc. ("we," "our" or the "Company") is filing this Exhibit 99.1 to our Current Report on Form 8-K (this "Exhibit") to recast certain changes described below with respect to the financial information contained in our Annual Report on Form 10-K for the fiscal y
Read more →APVOAPTEVO THERAPEUTICS ANNOUNCES THE LAUNCH OF ITS SECOND PLATFORM TECHNOLOGY ADAPTIR-FLEX TM AND INTRODUCES THE NEW BISPECIFIC PROSTATE CANCER CANDIDATE APVO442 New Bispecific Therapeutic Candidate AP
ANNOUNCES THE LAUNCH OF ITS SECOND PLATFORM TECHNOLOGY INTRODUCES THE NEW BISPECIFIC PROSTATE CANCER CANDIDATE APVO442 New Bispecific Therapeutic Candidate APVO442 uses ADAPTIR-FLEX Platform Technology APVO442 is a Unique T-Cell Engager Designed to Target PSMA and CD3 for the
Read more →APVOAPTEVO THERAPEUTICS and ALLIGATOR BIOSCIENCE ADVANCING THE BISPECIFIC 4-1BBx5T4 ANTIBODY ALG.APV-527 INTO PHASE 1
APTEVO THERAPEUTICS and ALLIGATOR BIOSCIENCE ADVANCING THE BISPECIFIC 4-1BBx5T4 ANTIBODY ALG.APV-527 INTO PHASE 1 CLINICAL DEVELOPMENT SEATTLE, WA - November 16, 2020 - Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology company focused on developing novel immuno
Read more →APVOAPTEVO THERAPEUTICS REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE $1.5 million of RUXIENCE Royalties Earned in the Third Quarter Funding Extends Cash Runway Into 2022 SEATTLE,
APTEVO THERAPEUTICS REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE $1.5 million of RUXIENCE Royalties Earned in the Third Quarter Funding Extends Cash Runway Into 2022 SEATTLE, WA - November 10, 2020 - Aptevo Therapeutics Inc. ("Aptevo" or "the Company")
Read more →APVOAPTEVO THERAPEUTICS ANNOUNCES SECOND COMPLETE REMISSION IN ONGOING APVO436 PHASE 1 CLINICAL TRIAL Second Complete Remission Observed in a Patient in Cohort 6 Enrollment in Cohort 8 Has Started Seattle, WA
THERAPEUTICS ANNOUNCES SECOND COMPLETE REMISSION ONGOING APVO436 PHASE 1 CLINICAL TRIAL Complete Remission Observed in a Patient in Cohort 6 in Cohort 8 Has Started WA - November 9, 2020 - Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ: APVO), a clinical-stage biotechnology com
Read more →APVOExhbit 99.1 APTEVO THERAPEUTICS ADOPTS LIMITED DURATION STOCKHOLDER RIGHTS PLAN Seattle, WA
DURATION STOCKHOLDER RIGHTS PLAN WA - November 8, 2020 - Aptevo Therapeutics Inc. ("Aptevo") (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR bispecific technology platform, today announced that i
Read more →APVOAPTEVO THERAPEUTICS SECURES $25 MILLION NON-DILUTIVE FINANCING FROM MIDCAP FINANCIAL TRUST Extends Cash Runway into Q3 2021 The Current Cash Balance is Anticipated to Create a Sufficient Timeline to Complete the APVO 436
SECURES $25 MILLION NON-DILUTIVE FINANCING FROM MIDCAP FINANCIAL TRUST Cash Balance is Anticipated to Create a Sufficient Timeline to Complete the APVO 436 Phase I(a) Dosing Cohorts Which Pre-Clinical Modelling Predicts May Deliver an Efficacious Dose WA - August 6, 2020 - Apt
Read more →APVOUNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On February 28, 2020, Aptevo Therapeutics Inc. ( Aptevo or the Company ) entered into an LLC Purchase Agreement (the Purchase Agreement ) with Medexus Pharma, Inc. ( Medexus ), pursuant to which Aptevo sold all of
Read more →APVOAptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia
SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designat
Read more →APVOAptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting
Preclinical Data Show That ALG.APV-527 is Well Tolerated with Repeated Dosing Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti-tumor Activity and Induces an Immunological Memory Response SEATTLE and LUND, Sweden, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeuti
Read more →APVOAPTEVO THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS Reports Record Net Revenue for IXINITY; Achieves 55% Increase in Year-over-Year Quarterly Net Revenue Advances APVO436 Phase 1/1b Cli
APTEVO THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS Reports Record Net Revenue for IXINITY; Achieves 55% Increase in Year-over-Year Quarterly Net Revenue Advances APVO436 Phase 1/1b Clinical Study in AML/MDS SEATTLE, WA - November 7, 2019 -- Aptevo Therapeutics I
Read more →APVOAptevo Therapeutics Reports Third Quarter 2019 Financial Results
Reports Record Net Revenue for IXINITY; Achieves 55% Increase in Year-over-Year Quarterly Net Revenue Advances APVO436 Phase 1/1b Clinical Study in AML/MDS SEATTLE, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on de
Read more →APVOAPTEVO THERAPEUTICS PROVIDES CORPORATE AND PIPELINE UPDATE Reports Record Quarterly IXINITY Net Revenue and New Patient Conversions Following Launch of New 3,000 IU Assay Provides Update on Ongoing
APTEVO THERAPEUTICS PROVIDES CORPORATE AND PIPELINE UPDATE Reports Record Quarterly IXINITY Net Revenue and New Patient Conversions Following Launch of New 3,000 IU Assay Provides Update on Ongoing APVO436 Phase 1/1b Clinical Study; Evidence of Potential Clinical Activity Eme
Read more →APVOAptevo Therapeutics Provides Corporate and Pipeline Update
Reports Record Quarterly IXINITY® Net Revenue and New Patient Conversions Following Launch of New 3,000 IU Assay Provides Update on Ongoing APVO436 Phase 1/1b Clinical Study; Evidence of Potential Clinical Activity Emerging; No Dose-Limiting Toxicities or Anti-drug Antibodies
Read more →APVOAptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors
New ADAPTIR Candidate APVO603 is a Dual-Agonistic Bispecific Antibody Targeting 4-1BB and OX40 APVO603 is Designed to Induce Synergistic Effects on Immune Responses with Potential to Enhance Anti-Tumor Immune Response Against Solid Tumors SEATTLE, Sept. 19, 2019 (GLOBE NEWSWI
Read more →APVOAptevo Therapeutics Reports Second Quarter 2019 Financial Results
Reports Positive Preliminary Top-Line Safety Data for APVO210 Phase 1 Single Ascending Dose (SAD) Clinical Study Advances APVO210 into Phase 1 Multiple Ascending Dose (MAD) Study Commences Dosing in Cohort 4 of APVO436 Phase 1 AML/MDS Clinical Trial Achieves 32% Increase in F
Read more →APVOAptevo Therapeutics Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share amounts, unaudited) For the Three Months Ended June 30, For the Six Months Ended
APTEVO THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS Reports Positive Preliminary Top-Line Safety Data for APVO210 Phase 1 Single Ascending Dose (SAD) Clinical Study Advances APVO210 into Phase 1 Multiple Ascending Dose (MAD) Study Commences Dosing in Cohort 4 of
Read more →APVOAptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol International Limited
SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the receipt of a $4.3 million milestone payment from Saol International Limited (Saol). Th
Read more →APVOAptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials
Completes Dosing in Single Ascending Dose (SAD) Phase 1 Study of APVO210 Receives Approval to Begin APVO210 Multiple Ascending Dose (MAD) Study Preliminary Data Suggest that Single Doses of APVO210 Appear to be Safe and Well Tolerated at Doses Equivalent to IL-10 Doses that Gen
Read more →APVOAptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B Patients
Expands Options for Patients with Potential for Reduced Reconstitution Time and Infusion Volume SEATTLE, June 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeuti
Read more →APVOAptevo Therapeutics Reports First Quarter 2019 Financial Results
Achieves 73% Increase in First Quarter 2019 Year-Over-Year IXINITY® Net Revenue On Target for Launch of New 3,000 IU IXINITY Assay Mid-2019 Advances Enrollment in APVO436 and APVO210 Phase 1 Clinical Studies; Anticipates Top-Line Preliminary Data Read-outs in the Third and Four
Read more →APVOAptevo Therapeutics Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share amounts, unaudited) For the Three Months Ended
APTEVO THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS Achieves 73% Increase in First Quarter 2019 Year-Over-Year IXINITY Net Revenue On Target for Launch of New 3,000 IU IXINITY Assay Mid-2019 Advances Enrollment in APVO436 and APVO210 Phase 1 Clinical Studies; Anti
Read more →APVOAptevo Therapeutics Reports IXINITY and Pipeline Progress
Reports 73% Increase in IXINITY Year-Over-Year Quarterly Net Revenue in Q1 2019 Anticipates Launching New IXINITY 3,000 IU Assay Mid-2019 Advances Dosing in Additional Cohorts in APVO436 and APVO210 Clinical Programs On Schedule to File a CTA for ALG.APV-527 in Q4 2019 SEATTL
Read more →APVOAptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting
APVO436 Preclinical Data Continue to Show Promising Results Supporting Clinical Development for the Treatment of Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS) and Differentiation from a Competitor Candidate Phase 1/1b Clinical Study of APVO436 Contin
Read more →APVOAptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting
SEATTLE, March 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that preclinical data for two of its ADAPTIR™ bispecific antibody candidates
Read more →APVOAptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases
Unique Mechanism of Action Suppresses Inflammation and Immune Activation Without Promoting Pro-Inflammatory Lymphocyte Stimulation Preliminary Phase 1 Data Read-outs Anticipated Q3 and Q4 2019 SEATTLE, March 20, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO),
Read more →APVOAptevo Therapeutics Inc. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share amounts) For the Year Ended
APTEVO THERAPEUTICS REPORTS 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Achieves Record Annual IXINITY Net Revenue of $23.1 Million Representing 111% Increase Over 2017 Advances APVO436 Into Phase 1/1b Clinical Trial for Treatment of Acute Myeloid Leukemia and High-G
Read more →APVOAptevo Therapeutics Reports 2018 Financial Results and Provides Business Update
Achieves Record Annual IXINITY® Net Revenue of $23.1 Million Representing 111% Increase Over 2017 Advances APVO436 Into Phase 1/1b Clinical Trial for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome Receives Authorization to Commence Dosing in Phase 1
Read more →APVOAptevo Announces Pricing of $22 Million Offering of Common Stock and Warrants
SEATTLE, March 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced the pricing of (i) for a combined public offering price of $1.00 per share of
Read more →APVOAptevo Announces Proposed Public Offering of Common Stock and Warrants
SEATTLE, March 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, sh
Read more →APVOSafe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including
Aptevo Therapeutics Highlights Key 2019 Priorities ADAPTIR Bispecific Antibody Candidates Poised to Progress in Clinical Development APVO436 Advancing in Phase 1 Clinical Trial for Acute Myeloid Leukemia; APVO210 Beginning Phase 1 Clinical Trial in Q1 2019; ALG.APV-527 Progre
Read more →APVOAptevo Therapeutics Highlights Key 2019 Priorities
ADAPTIR™ Bispecific Antibody Candidates Poised to Progress in Clinical Development APVO436 Advancing in Phase 1 Clinical Trial for Acute Myeloid Leukemia; APVO210 Beginning Phase 1 Clinical Trial in Q1 2019; ALG.APV-527 Progressing with CTA Submission in H2 2019 Projecting 1/
Read more →APVOAptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics
SEATTLE, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has collected $3.3 million in escrow funds from Saol Therapeutics related to a pur
Read more →APVOAptevo Therapeutics Announces Up To $35 Million Common Stock Purchase Agreement With Lincoln Park Capital
Provides Opportunistic Capital of up to $35 Million to Aptevo During the 36-month Term of the Agreement SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, a
Read more →APVOAptevo Therapeutics Doses First Patient in Phase 1/1b Clinical Trial of Lead Next-Generation Bispecific Antibody APVO436
Preclinical Data for APVO436 Show Potential Best-in-Class Attributes with Potent T-Cell Directed Tumor Killing and Reduced Cytokine Production Compared to a Competitor Construct Phase 1/1b Clinical Trial to Evaluate Safety Profile and Determine the Recommended Dose of APVO436 in
Read more →APVOAptevo Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
SEATTLE, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 30th Annual Piper Jaffray Healthcare Conference
Read more →APVOAbout the APVO414 mCRPC Clinical Study APVO414 is a first-generation bispecific antibody that that was built on Aptevo's ADAPTIR modular protein therapeutic platform and is designed to simultaneously target prostate spec
APTEVO THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS Achieves 132% Increase in IXINITY Quarterly Net Revenue Year-Over-Year More than Doubles Year-to-Date IXINITY Net Revenue from $8.1 Million to $16.7 Million Advances Bispecifics APVO436 and APVO210; On Track t
Read more →APVOAptevo Therapeutics Reports Third Quarter 2018 Financial Results
Achieves 132% Increase in IXINITY® Quarterly Net Revenue Year-Over-Year More than Doubles Year-to-Date IXINITY Net Revenue from $8.1 Million to $16.7 Million Advances Bispecifics APVO436 and APVO210; On Track to Commence Patient Dosing Q4 2018 and Q1 2019 Discontinues Clinical
Read more →APVOAptevo Therapeutics Announces Expanded Growth Initiatives for IXINITY
Plans to Introduce 3000 IU IXINITY Assay for Enhanced Patient Convenience Will Commence Pediatric Study Seeking U.S. Label Expansion Explores Ex-US Licensing and Partnership Collaborations to Expand International IXINITY Footprint SEATTLE, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Apt
Read more →APVOAptevo Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference
SEATTLE, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the Ladenburg Thalmann 2018 Healthcare Conference o
Read more →APVOAPTEVO THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS Achieves Record IXINITY Net Revenue with 94% Increase in Year-Over-Year Quarterly Revenue Publishes and Presents New Data on Multipl
APTEVO THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS Achieves Record IXINITY Net Revenue with 94% Increase in Year-Over-Year Quarterly Revenue Publishes and Presents New Data on Multiple ADAPTIR Bispecific Candidates Showing Robust Immune System Engagement and T-
Read more →APVOAptevo Therapeutics Reports Second Quarter 2018 Financial Results
Achieves Record IXINITY® Net Revenue with 94% Increase in Year-Over-Year Quarterly Revenue Publishes and Presents New Data on Multiple ADAPTIR™ Bispecific Candidates Showing Robust Immune System Engagement and T-cell Activation Advances APVO436 Toward Clinical Development for
Read more →APVOAptevo Therapeutics Revises Term Loan Agreement With MidCap Financial; Reduces Cash Requirements by $18 Million
Defers Principal Repayments to February 2020 and Reduces Restricted Cash Covenant Aptevo to Announce Second Quarter 2018 Financial Results on August 9, 2018 SEATTLE, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on de
Read more →APVOAbout Aptevo Therapeutics Inc. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients' lives. Aptevo has a commercial pro
APTEVO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS Almost Doubles Year-Over-Year IXINITY Quarterly Revenue Files IND for APVO436 and Advances APVO210 Toward a Planned Q4 2018 IND Submission Presents Data at AACR Annual Meeting Showing Best-in-Class Potential for
Read more →APVOAptevo Therapeutics Reports First Quarter 2018 Financial Results
Almost Doubles Year-Over-Year IXINITY Quarterly Revenue Files IND for APVO436 and Advances APVO210 Toward a Planned Q4 2018 IND Submission Presents Data at AACR Annual Meeting Showing Best-in-Class Potential for APVO436 Versus a Competitor Molecule SEATTLE, May 10, 2018 (GLOB
Read more →APVOAptevo Therapeutics Announces IND Submission for APVO436
New Preclinical Data Presented at AACR Support Best-in-Class Features of APVO436 Highlighting Reduced Cytokine Release and Antibody-Like Half-Life and Manufacturing On Track to Commence Phase 1 Clinical Trial of APVO436 in Acute Myeloid Leukemia and Myelodysplastic Syndrome in Q
Read more →APVOAptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release
New Preclinical Data Presented at the 2018 American Association for Cancer Research Annual Meeting Show Potent T-Cell Directed Tumor Killing with Reduced Cytokine Production Compared to a Competitor Bispecific Construct SEATTLE, April 16, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeu
Read more →APVOAptevo Therapeutics Reports 2017 Financial Results and Provides Business Update
Completes Sale of Hyperimmune Commercial Business for up to $74.5 Million Forms Strategic Bispecific Antibody Partnership with Alligator Bioscience Demonstrating Versatility of the ADAPTIR™ Technology Platform Advances Multiple ADAPTIR Candidates with Investigational New Drug A
Read more →APVOAptevo Therapeutics Presents New Patient-Reported Data With IXINITY
Data Presented at the Thrombosis and Hemostasis 2018 Summit of North America SEATTLE, March 12, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that new pat
Read more →APVOAptevo Therapeutics to Present at the 30th Annual ROTH Conference
SEATTLE, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 30th Annual ROTH Conference on Tuesday March 13th
Read more →APVOThis presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including our financial guidance
Aptevo Therapeutics Investor Presentation January 2018 Exhibit 99.1 This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including our financi
Read more →APVOAptevo Therapeutics Begins Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma
SEATTLE, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has commenced patient dosing in a Phase 2 clinical evaluation of otlertuzumab in a
Read more →APVOAptevo Therapeutics’ Novel Bispecific Antibody Therapeutic APVO436 Shows Broad Activity in Primary Human AML Samples
New APVO436 Preclinical Data Show Robust T-Cell Engagement and Cytotoxicity in AML Patient Specimens SEATTLE, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today
Read more →APVOAptevo Therapeutics Announces Plans to Conduct Phase 2 Study of Otlertuzumab in Peripheral T-Cell Lymphoma
Anticipates 2 IND Filings in 2018 for Novel Bispecific Antibody Candidates SEATTLE, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced recent developm
Read more →APVOAptevo Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference
SEATTLE, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 29th Annual Piper Jaffray Healthcare Conference o
Read more →APVOAptevo Therapeutics Reports Third Quarter 2017 Financial Results
Strengthened Cash Position to Support Ongoing R&D and Commercial Activities; Reported $107 Million in Cash at the End of the Third Quarter Expanded Novel Bispecific Antibody Portfolio Through Collaboration with Alligator Bioscience; Advanced New Bispecific Candidates Targeting
Read more →APVOautoimmune disease and inflammation. For more information, please visit www.aptevotherapeutics.com Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities
APTEVO THERAPEUTICS REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS Strengthened Cash Position to Support Ongoing R&D and Commercial Activities; Reported $107 Million in Cash at the End of the Third Quarter Expanded Novel Bispecific Antibody Portfolio Through Collaboration with A
Read more →APVOAptevo Therapeutics Presents New Preclinical Data on APVO436 – a Next Generation ADAPTIR™ Bispecific Antibody Candidate
New Preclinical Data Show APVO436 Demonstrates Rapid and Significant Reduction in Skeletal Tumor Burden in Mice with Well-Established and Disseminated Tumors SEATTLE, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on dev
Read more →APVOAptevo Therapeutics Showcases New Mechanism of Action for Its ADAPTIR Platform at the Inflammation Research Society Meeting
New Autoimmune Candidate APVO210 Demonstrates Targeted Cytokine Delivery for Application in Various Autoimmune and Inflammatory Diseases SEATTLE, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno
Read more →APVOAptevo Therapeutics Presents New Data on Enhanced Features of Its Next Generation ADAPTIR™ Bispecific Platform at the World Bispecific Summit
SEATTLE, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced that new information on the Company’s proprietary next generation ADAPTIR™ protein t
Read more →APVOAptevo Therapeutics Extends Cash Runway $20 Million; Retains Term Loan Agreement With MidCap Financial
SEATTLE, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, today announced that it has amended the terms of a credit agreement initially executed with MidCap
Read more →APVOAptevo Therapeutics Completes Sale of Hyperimmune Products for Up to $74.5 Million
Sharpens Focus on Innovative ADAPTIR® Bispecific Antibody Platform and IXINITY® Commercial Asset Strengthens Cash Position to Advance R&D and Commercial Strategy SEATTLE, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused
Read more →APVOAptevo Therapeutics Signs Agreement for Up to $74.5 Million to Sell Hyperimmune Commercial Products
Provides Significant Non-Dilutive Funding to Execute R&D Strategy Sharpens Focus on Proprietary ADAPTIR™ Protein Therapeutic Platform Retains IXINITY® Commercial Asset SEATTLE, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company fo
Read more →APVOAptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/ES414
Aptevo Regains Worldwide Rights to Novel Bispecific Prostate Cancer Immunotherapeutic MOR209/ES414 Preliminary Phase I Data Show Markedly Lower Anti-Drug Antibody Titers Demonstrating Effectiveness of New Dosing Regimen SEATTLE, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeu
Read more →APVOAptevo Therapeutics and Alligator Bioscience commence IND-enabling development activities for new bispecific immunotherapy candidate ALG.APV-527
Aptevo Therapeutics and Alligator Bioscience commence IND-enabling development activities for new bispecific immunotherapy candidate ALG.APV-527 Novel Bispecific Antibody Targeting Biological Pathway Implicated in Multiple Solid Tumor Indications Seattle, WA, and Lund, Sweden -
Read more →APVOAptevo Therapeutics Reports Second Quarter 2017 Financial Results
Showcases Differentiating Features of the ADAPTIR™ Protein Therapeutic Platform at Prominent Industry Conferences Signs Collaboration Agreement with Alligator Bioscience Expanding Aptevo’s Portfolio to Include a New Bispecific Antibody Candidate with a Novel Mechanism of Action
Read more →APVOAPTEVO THERAPEUTICS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS Showcases Differentiating Features of the ADAPTIR Protein Therapeutic Platform at Prominent Industry Conferences Signs Collaboration
APTEVO THERAPEUTICS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS Showcases Differentiating Features of the ADAPTIR Protein Therapeutic Platform at Prominent Industry Conferences Signs Collaboration Agreement with Alligator Bioscience Expanding Aptevo's Portfolio to Include a
Read more →APVOAptevo Therapeutics and Alligator Bioscience Announce Plans to Co-Develop Novel Bispecific Antibody for Tumor-Directed Immunotherapy
Strategic Partnership Will Advance Development of a Novel Bispecific Immuno-Oncology Antibody Targeting Compelling Biological Pathway Implicated in Multiple Solid Tumor Indications Focuses on New Mechanism of Action of Tumor Targeting Demonstrating the Versatility of Alligato
Read more →APVOOverview of ADAPTIR Bispecific Technology Bispecifics in Immuno-Oncology Next Generation ADAPTIR Candidates Portfolio of Preclinical Candidates ADAPTIR Lead Selection Process ADAPTIR Platform: Key CMC Advantages Summary
Developing Next-Generation ADAPTIRTM Molecules From the Bench to the Clinic BIO International 19-21 June, 2017 Aptevo Therapeutics Exhibit 99.1 Overview of ADAPTIR Bispecific Technology Bispecifics in Immuno-Oncology Next Generation ADAPTIR Candidates Portfolio of Preclinical Ca
Read more →APVOAptevo Therapeutics Highlights Key Features of Its ADAPTIR™ Protein Therapeutic Platform at Two Industry Conferences
SEATTLE, June 07, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, announced today that aspects of its ADAPTIR™ protein therapeutic platform were showcased recently at
Read more →APVOAptevo Therapeutics Reports First Quarter 2017 Financial Results
Expands ADAPTIR Portfolio and Announces New Bispecific Candidate; Presents Data at the 2016 PEPTALK Conference Showcasing Advantages of the ADAPTIR™ Platform SEATTLE, May 12, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on dev
Read more →APVOreliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement
APTEVO THERAPEUTICS REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS Expands ADAPTIR Portfolio and Announces New Bispecific Candidate; Presents Data at the 2016 PEPTALK Conference Showcasing Advantages of the ADAPTIR Platform SEATTLE, WA - May 12, 2017 -- Aptevo Therapeutics Inc. (
Read more →APVOAptevo Therapeutics Presents Detailed Overview of its Adaptir™ Protein Therapeutic Platform at the 13th Annual Pegs Summit
Key Advantages of the ADAPTIR Platform Showcased During the ‘Bispecific Antibodies in Oncology’ Session SEATTLE, May 05, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeut
Read more →APVOAptevo Therapeutics Presents New Clinical Data Evaluating the Safety and Efficacy of IXINITY in Children With Hemophilia B
Data Presented at the Hemostasis and Thrombosis Research Society 2017 Scientific Symposium SEATTLE, April 10, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announce
Read more →APVOAptevo Therapeutics’ Next Generation ADAPTIR™ Bispecific Antibody Candidates Show Potent Immune Activation
New Preclinical Data Presented at the 2017 American Association for Cancer Research Annual Meeting Demonstrate Antibody-like Characteristics and Efficacy of Redirected T-Cell Cytotoxicity Therapeutic Approach Antibody-like Serum Half-life in Mice of up to 12.5 days – Significant
Read more →APVOAPTEVO THERAPEUTICS REPORTS 2016 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Advances Multiple Clinical and Preclinical Candidates Based on the Company's Novel ADAPTIR Protein Therapeutic Platfor
APTEVO THERAPEUTICS REPORTS 2016 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Advances Multiple Clinical and Preclinical Candidates Based on the Company's Novel ADAPTIR Protein Therapeutic Platform Achieves 30% Increase in Year-Over-Year Product Sales Revenue SEATTLE, WA -
Read more →APVOAptevo Therapeutics Reports 2016 Financial Results and Provides Business Update
Advances Multiple Clinical and Preclinical Candidates Based on the Company’s Novel ADAPTIR™ Protein Therapeutic Platform Achieves 30% Increase in Year-Over-Year Product Sales Revenue SEATTLE, March 31, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechn
Read more →APVOAptevo Therapeutics Announces New IXINITY Supply Available May 2017
SEATTLE, March 15, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the successful manufacture of a recent bulk drug substance (BDS) batch of IXINITY® [Coagul
Read more →APVOAptevo Therapeutics Expands Bispecific Antibody Portfolio
SEATTLE, March 14, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that preclinical data for new bispecific antibody candidates targeting CD123 and CD3 will
Read more →APVOAptevo Therapeutics to Present at the 29th Annual ROTH Conference
SEATTLE, March 06, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 29th Annual ROTH Conference on Wednesday, March
Read more →APVOAptevo Therapeutics Receives $20 Million Payment From Emergent BioSolutions
SEATTLE, Jan. 13, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has received a $20 million cash payment from Emergent BioSolutions pursuant to a pr
Read more →APVOAptevo Therapeutics Presents Data on Its ADAPTIR™ Antibody Platform at the 16th Annual PEPTALK Conference
SEATTLE, Jan. 12, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that Dr. John Blankenship, a Lead Scientist at Aptevo, presented new data on the Company’s
Read more →APVOAptevo Therapeutics Resumes IXINITY Manufacturing; Anticipates Re-Entering the Market in the Second Quarter of 2017
SEATTLE, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has resumed IXINITY® manufacturing operations and anticipates that new supply of IX
Read more →APVOAptevo Therapeutics Announces Publication of Phase 2 Clinical Data for Otlertuzumab
SEATTLE, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO) a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the publication of positive data from a Phase 2 clinical trial evaluating its proprietary hu
Read more →APVOAptevo Therapeutics Amends Collaboration Agreement with MorphoSys AG for Novel Immunotherapeutic, MOR209/ES414
SEATTLE, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO) a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has amended the terms of its collaboration agreement with MorphoSys AG, originally e
Read more →APVOAptevo Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference
SEATTLE, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it will present at the 28th Annual Piper Jaffray Healthcare Conference on Wednesday, N
Read more →APVOAptevo Therapeutics Augments Leadership Team
Appoints Former GlaxoSmithKline Executive Randy Maddux Senior Vice President, Operations Jane Gross, Ph.D., Promoted to Senior Vice President and Chief Scientific Officer SEATTLE, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology compan
Read more →APVOAugust 2016 Aptevo Therapeutics Investor Presentation Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any state
August 2016 Aptevo Therapeutics Investor Presentation AGENDA Leadership in Bispecific Antibody Development Aptevo today What sets us apart Summary Aptevo: At a Glance Focus Oncology/Hematology Commercial Products 4 Product Pipeline Platform Technologies Employees Clinical: 2 Pr
Read more →Competitive Position
How APVO ranks across every disease it competes inCompetitive Position is a premium feature
See how APVO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial